跳转至内容
Merck

T8885

Sigma-Aldrich

Thrombin 来源于人类血浆

lyophilized powder, Suitable for routine use in the thrombin time test

别名:

IIa因子

登录查看公司和协议定价


About This Item

CAS号:
EC號碼:
MDL號碼:
分類程式碼代碼:
12352204
NACRES:
NA.54

生物源

human plasma

品質等級

形狀

lyophilized powder

包裝

vial of ≥10 NIH units

雜質

HIV, hepatitis B and hepatitis C, tested negative

UniProt登錄號

儲存溫度

−20°C

基因資訊

human ... F2(2147)

正在寻找类似产品? 访问 产品对比指南

一般說明

凝血酶是止血过程中的最终凝血蛋白酶,可同时促进促凝血和抗凝血作用。

應用

凝血酶被用于重组融合蛋白的位点特异性切割,这些重组融合蛋白具有可接近的凝血酶识别位点以除去亲和标签。已有研究使用凝血酶比较了低分子量肝素(LMWH)与其他抗凝剂作为大型矫形手术的静脉血栓栓塞预防剂的疗效和安全性。

生化/生理作用

选择性裂解纤维蛋白原中 Arg-Gly 键形成纤维蛋白和纤维蛋白肽 A 和 B 的丝氨酸蛋白酶。

單位定義

活性以 NIH 单位表示,通过与 NIH 凝血酶参考标准品的直接比较获得

重構

当使用1 ml H2O重悬时,一瓶含有10 mg牛血清白蛋白、0.15 M NaCl和0.05 M柠檬酸钠,pH 6.5

分析報告

NIH 试验步骤基于 Biggs 方法的改进,使用 0.2mL 稀释血浆(与生理盐水 1:1 混合,作为底物)和 0.1mL Biggs 凝血酶样品(稳定于 1% 缓冲白蛋白溶液中)。只使用 15-25 秒之间的凝血时间分析凝血酶浓度。

其他說明

免責聲明

供研究使用。在法国,在用于科研目的时(包括进口和出口活动(《公共健康法》第L 1211-1条,第2节))该产品为管制品。购买者(即最终用户)需要获得《公共健康法》法第L 1211-1条规定的法国研究部的进口授权。订购本产品即表明您确认已经获得合适的进口授权。

象形圖

Health hazardExclamation mark

訊號詞

Danger

危險分類

Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - STOT SE 3

標靶器官

Respiratory system

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 2

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Diana M Sobieraj et al.
Pharmacotherapy, 32(9), 799-808 (2012-06-30)
To evaluate the comparative efficacy and safety of low-molecular-weight heparins (LMWHs) versus other anticoagulants as venous thromboembolism prophylaxis in major orthopedic surgery. Systematic review with meta-analysis of 37 randomized controlled trials. Patients undergoing total hip replacement, total knee replacement, or
Michael Hultström et al.
Biomedicines, 10(6) (2022-06-25)
Hypercoagulation and endothelial dysfunction play central roles in severe forms of COVID-19 infections, but the molecular mechanisms involved are unclear. Increased plasma levels of the inflammatory cytokine and TIE2 receptor antagonist Angiopoietin-2 were reported in severely ill COVID-19 patients. In
Deepti Sharma et al.
Communications biology, 5(1), 479-479 (2022-05-20)
Pathological retinal neovascularization (NV) is a clinical manifestation of various proliferative retinopathies, and treatment of NV using anti-VEGF therapies is not selective, as it also impairs normal retinal vascular growth and function. Here, we show that genetic deletion or siRNA-mediated
Michael Ablinger et al.
International journal of molecular sciences, 22(7) (2021-04-04)
Intermediate junctional epidermolysis bullosa caused by mutations in the COL17A1 gene is characterized by the frequent development of blisters and erosions on the skin and mucous membranes. The rarity of the disease and the heterogeneity of the underlying mutations renders
Somasundaram Raghavan et al.
The Journal of biological chemistry, 293(27), 10574-10589 (2018-05-20)
Although signaling of thrombin via its receptor protease-activated receptor 1 (Par1) is known to occur in atherothrombosis, its link to the actual pathogenesis of this condition is less clear. To better understand the role of thrombin-Par1 signaling in atherosclerosis, here

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门